A putative therapeutic target in hepatocellular carcinoma: Q9H869

Ablatotech Signals reports today on a putative therapeutic target — Q9H869 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in hepatocellular carcinoma.

Background

The putative target Q9H869, also known as "Hypothetical protein LOC100507160," has emerged as a candidate of interest in the context of hepatocellular carcinoma (HCC). Given the rising incidence of HCC and the limited therapeutic options currently available, exploring novel targets such as Q9H869 could provide insights into potential therapeutic strategies. Preliminary expression profiling suggests that Q9H869 may play a role in HCC biology, warranting further investigation into its functional relevance and therapeutic potential.

Data-mining rationale

The rationale for investigating Q9H869 stems from a comprehensive data-mining effort that cross-referenced reviewed human entries in UniProt associated with hepatocellular carcinoma against 1,141 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, Q9H869 was identified in several expression-profiling studies, yet it lacks a registered Phase 1 or higher clinical program, indicating a potential gap in the exploration of this candidate. This analysis highlights the need for further scrutiny of Q9H869's role in HCC.

Why prior analyses may have missed this

Many of the GEO datasets that included Q9H869 predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which allows for more robust multiple-testing corrections. Consequently, earlier analyses may not have accurately captured the expression dynamics of Q9H869 in HCC. The absence of rigorous statistical validation may have led to an underappreciation of its potential significance in the disease context.

Reasoning for further validation

To substantiate the potential role of Q9H869 in hepatocellular carcinoma, several experimental approaches are suggested: 1. **Re-analyze matched GEO datasets**: Employ the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to identify differentially expressed genes, including Q9H869. 2. **Validate top differentially-expressed genes**: Conduct quantitative PCR (qPCR) in an independent cohort of HCC samples to confirm the expression levels of Q9H869 and other top candidates. 3. **Check tissue specificity**: Utilize resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess the tissue-specific expression patterns of Q9H869. 4. **Run pathway context analyses**: Utilize tools like STRING and OmniPath to explore the potential pathways and interactions involving Q9H869, providing insights into its biological role. 5. **Assess druggability**: If validation of Q9H869's expression and function is achieved, evaluate its druggability using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References

UniProt. Q9H869 - Hypothetical protein LOC100507160. [Link](https://www.uniprot.org/uniprot/Q9H869)
NCBI GEO. GDS:200277244, GDS:200305769, GDS:200309883, GDS:200143870, GDS:200289533. [Link](https://www.ncbi.nlm.nih.gov/geo/)
Ritchie ME, et al. (2015). "Limma powers differential expression analyses for RNA-sequencing and microarray studies." *Nucleic Acids Research*, 43(7): e47. DOI: 10.1093/nar/gkv007
GTEx Portal. [Link](https://gtexportal.org/)
Human Protein Atlas. [Link](https://www.proteinatlas.org/)

References